

Arnt F A Schellekens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6087807/publications.pdf>

Version: 2024-02-01

108
papers

2,569
citations

331670

21
h-index

243625

44
g-index

121
all docs

121
docs citations

121
times ranked

3393
citing authors

#	ARTICLE	IF	CITATIONS
1	Improving Medical Studentsâ€™ Attitude toward Patients with Substance use Problems through Addiction Medicine Education. <i>Substance Abuse</i> , 2022, 43, 47-55.	2.3	10
2	Development of a personalised substance use disorder treatment for people with mild intellectual disabilities or borderline intellectual functioning: An intervention mapping approach. <i>Journal of Intellectual and Developmental Disability</i> , 2022, 47, 131-140.	1.6	3
3	Safety of ibogaine administration in detoxification of opioidâ€dependent individuals: a descriptive openâ€label observational study. <i>Addiction</i> , 2022, 117, 118-128.	3.3	20
4	Effects of opioid rotation to buprenorphine/naloxone on pain, pain thresholds, pain tolerance, and quality of life in patients with chronic pain and opioid use disorder. <i>Pain</i> , 2022, 163, 955-963.	4.2	5
5	Measuring Integrated Novel Dimensions in Neurodevelopmental and Stress-Related Mental Disorders (MIND-SET): Protocol for a Cross-sectional Comorbidity Study From a Research Domain Criteria Perspective. <i>Jmirx Med</i> , 2022, 3, e31269.	0.4	9
6	Effects of family history of substance use disorder on reward processing in adolescents with and without attentionâ€deficit/hyperactivity disorder. <i>Addiction Biology</i> , 2022, 27, e13137.	2.6	3
7	rTMS Reduces Craving and Alcohol Use in Patients with Alcohol Use Disorder: Results of a Randomized, Sham-Controlled Clinical Trial. <i>Journal of Clinical Medicine</i> , 2022, 11, 951.	2.4	9
8	Against All Odds? Addiction History Associated with Better Viral Hepatitis Care: A Dutch Nationwide Claims Data Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 1146.	2.4	0
9	Monitoring Opioids in Europe: The Need for Shared Definitions and Measuring Drivers of Opioid Use and Related Harms. <i>European Addiction Research</i> , 2022, 28, 231-240.	2.4	12
10	Authors' Response to Peer Reviews of â€Measuring Integrated Novel Dimensions in Neurodevelopmental and Stress-Related Mental Disorders (MIND-SET): Protocol for a Cross-sectional Comorbidity Study From a Research Domain Criteria Perspectiveâ€ Jmirx Med, 2022, 3, e36212.	0.4	0
11	Network Analysis of DSM Symptoms of Substance Use Disorders and Frequently Co-Occurring Mental Disorders in Patients with Substance Use Disorder Who Seek Treatment. <i>Journal of Clinical Medicine</i> , 2022, 11, 2883.	2.4	3
12	Investigating genetic correlation and causality between nicotine dependence and <sc>ADHD</sc> in a broader psychiatric context. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2021, 186, 423-429.	1.7	13
13	The relationship between depressive symptoms, general psychopathology, and wellâ€being in patients with major depressive disorder. <i>Journal of Clinical Psychology</i> , 2021, 77, 1472-1486.	1.9	7
14	Effects of substance misuse on reward-processing in patients with attention-deficit/hyperactivity disorder. <i>Neuropsychopharmacology</i> , 2021, 46, 622-631.	5.4	7
15	Successful Treatment of Severe, Treatment Resistant GHB Withdrawal through Thiopental-Coma. <i>Substance Abuse</i> , 2021, 42, 33-38.	2.3	4
16	Success Rates of Monitoring for Healthcare Professionals with a Substance Use Disorder: A Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 264.	2.4	7
17	Is Europe facing an opioid crisis like the United States? An analysis of opioid use and related adverse effects in 19 European countries between 2010 and 2018. <i>European Psychiatry</i> , 2021, 64, e47.	0.2	47
18	Associations between the <i>CADM2</i> gene, substance use, risky sexual behavior, and selfâ€control: A phenomeâ€wide association study. <i>Addiction Biology</i> , 2021, 26, e13015.	2.6	15

#	ARTICLE	IF	CITATIONS
19	Responding to COVID-19: Emerging Practices in Addiction Medicine in 17 Countries. <i>Frontiers in Psychiatry</i> , 2021, 12, 634309.	2.6	7
20	Substance use, Unlike Dolutegravir, is Associated with Mood Symptoms in People Living with HIV. <i>AIDS and Behavior</i> , 2021, 25, 4094-4101.	2.7	0
21	Characterization of the GHB Withdrawal Syndrome. <i>Journal of Clinical Medicine</i> , 2021, 10, 2333.	2.4	9
22	Effects of substance misuse on inhibitory control in patients with attention-deficit/hyperactivity disorder. <i>Addiction Biology</i> , 2021, , e13063.	2.6	1
23	Treatment of Adolescents with Concurrent Substance Use Disorder and Attention-Deficit/Hyperactivity Disorder: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 3908.	2.4	7
24	Beneficial Effects of Opioid Rotation to Buprenorphine/Naloxone on Opioid Misuse, Craving, Mental Health, and Pain Control in Chronic Non-Cancer Pain Patients with Opioid Use Disorder. <i>Journal of Clinical Medicine</i> , 2021, 10, 3727.	2.4	4
25	Clinical Relevance of Immersive Virtual Reality in the Assessment and Treatment of Addictive Disorders: A Systematic Review and Future Perspective. <i>Journal of Clinical Medicine</i> , 2021, 10, 3658.	2.4	18
26	The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 128, 789-818.	6.1	483
27	Effects of substance misuse and current family history of substance use disorder on brain structure in adolescents and young adults with attention-deficit/hyperactivity disorder. <i>Drug and Alcohol Dependence</i> , 2021, 228, 109032.	3.2	2
28	If the mountain won't come to Mohammed, then Mohammed must go to the mountain: Decentralisation of hepatitis C care for people who use drugs. <i>United European Gastroenterology Journal</i> , 2021, 9, 1101-1102.	3.8	2
29	Unbiased Metabolomics Links Fatty Acid Pathways to Psychiatric Symptoms in People Living with HIV. <i>Journal of Clinical Medicine</i> , 2021, 10, 5466.	2.4	4
30	Youth in transition: Study protocol of a prospective cohort study into the long-term course of addiction, mental health problems and social functioning in youth entering addiction treatment. <i>BMC Psychiatry</i> , 2021, 21, 605.	2.6	4
31	Effectiveness of a group intervention to reduce sexual transmission risk behavior among MSM living with HIV: a non-randomized controlled pilot study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, , 1-12.	1.2	1
32	Response to Luz & Mash on cardiac toxicity of ibogaine. <i>Addiction</i> , 2021, , .	3.3	0
33	The relationship between childhood adversity and adult personality revealed by network analysis. <i>Child Abuse and Neglect</i> , 2020, 99, 104254.	2.6	17
34	Onset and Severity of Early Disruptive Behavioral Disorders in Treatment-Seeking Substance Use Disorder Patients with and without Attention-Deficit/Hyperactivity Disorder. <i>European Addiction Research</i> , 2020, 26, 211-222.	2.4	4
35	Effects of Substance Misuse and Family History of Substance Use Disorder on Delay Discounting in Adolescents and Young Adults with Attention-Deficit/Hyperactivity Disorder. <i>European Addiction Research</i> , 2020, 26, 295-305.	2.4	4
36	Exploring Brain Derived Neurotrophic Factor and Cell Adhesion Molecules as Biomarkers for the Transdiagnostic Symptom Anhedonia in Alcohol Use Disorder and Comorbid Depression. <i>Frontiers in Psychiatry</i> , 2020, 11, 296.	2.6	17

#	ARTICLE	IF	CITATIONS
37	Attention Deficit Hyperactivity Disorder Increases Nicotine Addiction Severity in Adults Seeking Treatment for Substance Use Disorders: The Role of Personality Disorders. <i>European Addiction Research</i> , 2020, 26, 191-200.	2.4	8
38	Sex, Drugs, and Impulse Regulation: A Perspective on Reducing Transmission Risk Behavior and Improving Mental Health Among MSM Living With HIV. <i>Frontiers in Psychology</i> , 2020, 11, 1005.	2.1	7
39	Validity of the ADHD module of the Mini International Neuropsychiatric Interview PLUS for screening of adult ADHD in treatment seeking substance use disorder patients: ADHD screening with MINI-Plus. <i>Revista De Psiquiatria Y Salud Mental</i> , 2020, , .	1.8	6
40	The International Collaboration on ADHD and Substance Abuse (ICASA): Mission, Results, and Future Activities. <i>European Addiction Research</i> , 2020, 26, 173-178.	2.4	15
41	Often Overlooked and Ignored, but Do Not Underestimate Its Relevance: ADHD in Addiction – Addiction in ADHD. <i>European Addiction Research</i> , 2020, 26, 169-172.	2.4	7
42	Tackling rising numbers of opioid prescriptions users. <i>Lancet Public Health</i> , The, 2020, 5, e139.	10.0	2
43	Physicians' norms and attitudes towards substance use in colleague physicians: A cross-sectional survey in the Netherlands. <i>PLoS ONE</i> , 2020, 15, e0231084.	2.5	13
44	Effects of Recreational GHB Use and Multiple GHB-Induced Comas on Brain Structure and Impulsivity. <i>Frontiers in Psychiatry</i> , 2020, 11, 166.	2.6	8
45	Trends in use and misuse of opioids in the Netherlands: a retrospective, multi-source database study. <i>Lancet Public Health</i> , The, 2019, 4, e498-e505.	10.0	134
46	Iatrogenic opioid use disorder, chronic pain and psychiatric comorbidity: A systematic review. <i>General Hospital Psychiatry</i> , 2019, 59, 37-50.	2.4	39
47	Reward processing in Attention-Deficit/Hyperactivity Disorder and healthy controls at high risk for Substance Use Disorders. <i>European Neuropsychopharmacology</i> , 2019, 29, S485-S486.	0.7	0
48	Neuropsychiatric symptoms in Tanzanian HIV-infected children receiving long-term efavirenz treatment: a multicentre, cross-sectional, observational study. <i>Lancet HIV</i> , the, 2019, 6, e250-e258.	4.7	9
49	Associations between impulsivity, risk behavior and HIV, HBV, HCV and syphilis seroprevalence among female prisoners in Indonesia: A cross-sectional study. <i>PLoS ONE</i> , 2019, 14, e0207970.	2.5	15
50	Neurodevelopmental and behavioral consequences of perinatal exposure to the HIV drug efavirenz in a rodent model. <i>Translational Psychiatry</i> , 2019, 9, 84.	4.8	9
51	Toxic Leukoencephalopathy Presenting as Lethal Catatonia. <i>Journal of Addiction Medicine</i> , 2019, 13, 241-244.	2.6	5
52	Delayed complications after severe clozapine intoxication. <i>International Clinical Psychopharmacology</i> , 2019, 34, 269-272.	1.7	5
53	Detoxification of a Patient With Comorbid Dependence on Phenibut and Benzodiazepines by Tapering With Baclofen. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 511-514.	1.4	10
54	Excellent reliability and validity of the Addiction Medicine Training Need Assessment Scale across four countries. <i>Journal of Substance Abuse Treatment</i> , 2019, 99, 61-66.	2.8	8

#	ARTICLE	IF	CITATIONS
55	International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder. <i>European Addiction Research</i> , 2018, 24, 43-51.	2.4	108
56	Baclofen to Prevent Relapse in Gamma-Hydroxybutyrate (GHB)-Dependent Patients: A Multicentre, Open-Label, Non-Randomized, Controlled Trial. <i>CNS Drugs</i> , 2018, 32, 437-442.	5.9	22
57	Safety Evaluation of Efavirenz in Children: Don't Forget the Central Nervous System. <i>Clinical Infectious Diseases</i> , 2018, 66, 1150-1150.	5.8	0
58	Efavirenz is related to neuropsychiatric symptoms among adults, but not among adolescents living with human immunodeficiency virus in Kilimanjaro, Tanzania. <i>Tropical Medicine and International Health</i> , 2018, 23, 164-172.	2.3	10
59	The Perception of Substance Use Disorder Among Clinicians, Caregivers and Family Members of Individuals With Intellectual and Developmental Disabilities. <i>Journal of Mental Health Research in Intellectual Disabilities</i> , 2018, 11, 54-68.	2.0	6
60	Substance use and nicotine dependence in persistent, remittent, and late-onset ADHD: a 10-year longitudinal study from childhood to young adulthood. <i>Journal of Neurodevelopmental Disorders</i> , 2018, 10, 42.	3.1	24
61	Relating addiction and psychiatric disorders. <i>Science</i> , 2018, 361, 1323-1324.	12.6	16
62	Cost-Effectiveness Analysis of Genotype-Guided Treatment Allocation in Patients with Alcohol Use Disorders Using Naltrexone or Acamprostate, Using a Modeling Approach. <i>European Addiction Research</i> , 2018, 24, 245-254.	2.4	9
63	Hallucinogen Persisting Perception Disorder After Ibogaine Treatment for Opioid Dependence. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 646-648.	1.4	7
64	Biochemical Effects on the Liver of 1 Month of Alcohol Abstinence in Moderate Alcohol Consumers. <i>Alcohol and Alcoholism</i> , 2018, 53, 435-438.	1.6	13
65	Disruption of Reward Processing in Addiction. <i>JAMA Psychiatry</i> , 2017, 74, 387.	11.0	319
66	Dried Blood Spot sampling in psychiatry: Perspectives for improving therapeutic drug monitoring. <i>European Neuropsychopharmacology</i> , 2017, 27, 205-216.	0.7	27
67	Behavioural addictions: Classification and consequences. <i>European Psychiatry</i> , 2017, 44, 187-188.	0.2	14
68	Are There Differences in Disruptions of Reward Processing Between Substance Use Disorder and Gambling Disorder? Reply. <i>JAMA Psychiatry</i> , 2017, 74, 760.	11.0	1
69	The role of the habenula in the transition from reward to misery in substance use and mood disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 80, 276-285.	6.1	71
70	Pharmacological Treatment in γ -Hydroxybutyrate (GHB) and γ -Butyrolactone (GBL) Dependence: Detoxification and Relapse Prevention. <i>CNS Drugs</i> , 2017, 31, 51-64.	5.9	44
71	Core Addiction Medicine Competencies for Doctors: An International Consultation on Training. <i>Substance Abuse</i> , 2017, 38, 483-487.	2.3	20
72	Staging & profiling in addiction, can we cross the gap from bench to bedside?. <i>European Psychiatry</i> , 2017, 41, S34-S35.	0.2	0

#	ARTICLE	IF	CITATIONS
73	A Brief Outline of the Use of New Technologies for Treating Substance Use Disorders in the European Union. <i>European Addiction Research</i> , 2017, 23, 177-181.	2.4	9
74	Psilocybin for treating substance use disorders?. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 203-212.	2.8	56
75	Disruption of reward-processing in addiction unravelled by image based meta-analysis of fMRI studies. <i>European Neuropsychopharmacology</i> , 2017, 27, S557.	0.7	2
76	A Review of Instruments for Screening and Diagnosis of Cocaine Use. , 2017, , 599-607.		0
77	Xylazine Dependence and Detoxification: A Case Report. <i>Psychosomatics</i> , 2016, 57, 529-533.	2.5	11
78	Treatment of heroin dependence with ibogaine. <i>European Psychiatry</i> , 2016, 33, S10-S11.	0.2	1
79	Rethinking the risk-benefit ratio of efavirenz in HIV-infected children. <i>Lancet Infectious Diseases</i> , The, 2016, 16, e76-e81.	9.1	16
80	Addiction training for health professionals as an antidote to the addiction health burden in Indonesia. <i>Addiction</i> , 2016, 111, 1498-1499.	3.3	3
81	Translational perspectives in addiction psychiatry. <i>European Psychiatry</i> , 2016, 33, S60-S60.	0.2	0
82	Ibogaine and addiction in the animal model, a systematic review and meta-analysis. <i>Translational Psychiatry</i> , 2016, 6, e826-e826.	4.8	42
83	Dopamine and serotonin genetic risk scores predicting substance and nicotine use in attention deficit/hyperactivity disorder. <i>Addiction Biology</i> , 2016, 21, 915-923.	2.6	19
84	Good Psychometric Properties of the Addiction Version of the Revised Illness Perception Questionnaire for Health Care Professionals. <i>PLoS ONE</i> , 2016, 11, e0164262.	2.5	10
85	Substance Misuse Education for Physicians: Why Older People are Important. <i>Yale Journal of Biology and Medicine</i> , 2016, 89, 97-103.	0.2	5
86	Effectiveness and Organization of Addiction Medicine Training Across the Globe. <i>European Addiction Research</i> , 2015, 21, 223-239.	2.4	48
87	Familial liability for metoprolol-induced psychosis. <i>General Hospital Psychiatry</i> , 2015, 37, 620.e5-620.e6.	2.4	7
88	Baclofen as relapse prevention in the treatment of Gamma-Hydroxybutyrate (GHB) dependence: an open label study. <i>BMC Psychiatry</i> , 2015, 15, 91.	2.6	15
89	Co-morbid anxiety disorders predict early relapse after inpatient alcohol treatment. <i>European Psychiatry</i> , 2015, 30, 128-136.	0.2	84
90	Improvement of Depression and Anxiety After Discontinuation of Long-Term Efavirenz Treatment. <i>CNS and Neurological Disorders - Drug Targets</i> , 2015, 14, 811-818.	1.4	25

#	ARTICLE	IF	CITATIONS
91	Establishing the Dopamine Dependency of Human Striatal Signals During Reward and Punishment Reversal Learning. <i>Cerebral Cortex</i> , 2014, 24, 633-642.	2.9	83
92	Do cognitive measures of response inhibition differentiate between attention deficit/hyperactivity disorder and borderline personality disorder?. <i>Psychiatry Research</i> , 2014, 215, 733-739.	3.3	18
93	<i>COMT</i> Val158Met modulates the effect of childhood adverse experiences on the risk of alcohol dependence. <i>Addiction Biology</i> , 2013, 18, 344-356.	2.6	39
94	Anatomical connection strength predicts dopaminergic drug effects on fronto-striatal function. <i>Psychopharmacology</i> , 2013, 227, 521-531.	3.1	27
95	A family history of alcoholism relates to alexithymia in substance use disorder patients. <i>Comprehensive Psychiatry</i> , 2013, 54, 911-917.	3.1	11
96	Excellent reliability of the Hamilton Depression Rating Scale (HDRS-21) in Indonesia after training. <i>Asia-Pacific Psychiatry</i> , 2013, 5, 141-146.	2.2	3
97	Dopaminergic drug effects during reversal learning depend on anatomical connections between the orbitofrontal cortex and the amygdala. <i>Frontiers in Neuroscience</i> , 2013, 7, 142.	2.8	12
98	The Level of Alexithymia in Alcohol-Dependent Patients Does Not Influence Outcomes after Inpatient Treatment. <i>American Journal of Drug and Alcohol Abuse</i> , 2012, 38, 299-304.	2.1	21
99	Reduced Dopamine Receptor Sensitivity as an Intermediate Phenotype in Alcohol Dependence and the Role of the COMT Val158Met and DRD2 Taq1A Genotypes. <i>Archives of General Psychiatry</i> , 2012, 69, 339.	12.3	46
100	Damage in the dorsal striatum alleviates addictive behavior. <i>General Hospital Psychiatry</i> , 2012, 34, 702.e9-702.e11.	2.4	12
101	Early Onset Alcohol Dependence Increases the Acoustic Startle Reflex. <i>Alcoholism: Clinical and Experimental Research</i> , 2012, 36, 1075-1083.	2.4	11
102	Psychotic symptoms in the course of sunitinib treatment for advanced renal cell cancer. Two cases. <i>General Hospital Psychiatry</i> , 2011, 33, 83.e1-83.e3.	2.4	10
103	Effect of apomorphine on cognitive performance and sensorimotor gating in humans. <i>Psychopharmacology</i> , 2010, 207, 559-569.	3.1	20
104	Alcohol dependence and anxiety increase error-related brain activity. <i>Addiction</i> , 2010, 105, 1928-1934.	3.3	48
105	The dopamine agonist apomorphine differentially affects cognitive performance in alcohol dependent patients and healthy controls. <i>European Neuropsychopharmacology</i> , 2009, 19, 68-73.	0.7	13
106	P.4.15 The COMT Val158Met genotype and prefrontal dopamine sensitivity in alcohol dependent patients and healthy controls. <i>European Neuropsychopharmacology</i> , 2009, 19, S91-S92.	0.7	0
107	P.6.a.013 Error processing in alcohol dependence. <i>European Neuropsychopharmacology</i> , 2008, 18, S526.	0.7	0
108	Disrupted sensorimotor gating due to mental fatigue: Preliminary evidence. <i>International Journal of Psychophysiology</i> , 2006, 62, 168-174.	1.0	59